Prediction of time-averaged concentration of haemoglobin in haemodialysis patients

Nephrology Dialysis Transplantation

Volumn 18, Issue 10, 2003, Pages 2082-2087

  Krisper, Peter ^a   Quehenberger, Franz ^a   Schneditz, Daniel ^a   Holzer, Herwig ^a   Polaschegg, Hans Dietrich ^b  

^a UNIVERSITY OF GRAZ   (Austria)

^b NONE

Author keywords

Haemodialysis; Haemoglobin; Post dialysis; Prediction; Target; Time averaged

Indexed keywords

DIALYSIS FLUID; HEMOGLOBIN;

ADULT; ANALYTIC METHOD; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CALCULATION; CONTROLLED STUDY; FEMALE; HEMODIALYSIS; HEMOGLOBIN DETERMINATION; HUMAN; LINEAR REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; POSTOPERATIVE PERIOD; PREDICTION; PREOPERATIVE PERIOD; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; TIME; ULTRAFILTRATION;

ADULT; AGED; ANEMIA; BLOOD CHEMICAL ANALYSIS; FEMALE; HEMOGLOBINS; HUMANS; KIDNEY FAILURE, CHRONIC; LINEAR MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREDICTIVE VALUE OF TESTS; PROBABILITY; RENAL DIALYSIS; RISK ASSESSMENT; SAMPLING STUDIES; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; TIME FACTORS;

EID: 0141507013     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/gfg355     Document Type: Article

References (24)

1. Eschbach JW, Egrie JC, Downing MR, Browne JK, Adamson JW. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin: results of combined phase I and II clinical trial. N Engl J Med 1987; 316: 73-78
2. Sunder-Plassmann G, Hörl WH. Effect of erythropoietin on cardiovascular diseases. Am J Kidney Dis 2001; 38 [Suppl 1]: 20-25
3. Beuerstein KM, Nissenson AR, Port FK, Kelly M, Steinwald B, Ware JE Jr. The effects of recombinant human erythropoietin on functional health and well-being in chronic dialysis patients. J Am Soc Nephrol 1996; 7: 763-773
4. Collins AJ. Influence of target hemoglobin in dialysis patients on morbidity and mortality. Kidney Int 2002; 61 [Suppl 80]: 44-48
5. Kaufman JS. Subcutaneous erythropoietin therapy: efficacy and economic implications. Am J Kidney Dis 1998; 32 [Suppl 4]: 147-151
6. Moreno F, Sanz-Guajardo D, Lopez-Gomez JM, Jofre R, Valderrabano F. Increasing the hematocrit has a beneficial effect on quality of life and is safe in selected hemodialysis patients. J Am Soc Nephrol 2000; 11: 335-342
7. Canadian Erythropoietin Study Group. Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving hemodialysis. Br Med J 1990; 300: 573-578
8. Besarab A, Bolton WK, Browne JK et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998; 339: 584-590
9. Foley RN, Parfrey PS, Morgan J et al. Effect of hemoglobin levels in hemodialysis patients with asymptomatic cardiomyopathy. Kidney Int 2000; 58: 1325-1335
10. National Kidney Foundation. NKF-K/DOQI: clinical practice guidelines for anemia of chronic kidney disease: Update 2000. Am J Kidney Dis 2001; 37 [Suppl 1]: 182-238
11. European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 1999; 14 [Suppl 5]: 1-50
12. Steuer RR, Germain MJ, Leypoldt JK. The variability of predialysis haematocrit during routine haemodialysis is high [abstract]. Nephrol Dial Transplant 1997; 12: 132A
13. Bellizzi V, Minutolo R, Terracciano V et al. Influence of the cyclic variation of hydration status on hemoglobin levels in hemodialysis patients. Am J Kidney Dis 2002; 40: 549-555
14. Paganim EP. Adapting the dialysis unit to increased hematocrit levels. Am J Kidney Dis 1995; 25 [Suppl 1]: 12-17
15. Movilli E, Pertica N, Camerini C et al. Predialysis versus postdialysis hematocrit evaluation during erythropoietin therapy. Am J Kidney Dis 2002; 39: 850-853
16. Vlassopoulos D, Sonikian M, Dardioti V, Hadjiconstaninou V. Target haematocrit during eythropoietin treatment in dialysis patients. Which value is 'true-functional haematocrit'? Nephrol Dial Transplant 1999; 14: 1340
17. Ritz E, Amann K. Optimal haemoglobin during treatment with recombinant human erythropoietin. Nephrol Dial Transplant 1998; 13 [Suppl 2]: 16-22
18. Cheriex EC, Leunissen KML, Janssen JHA, Mooy JMV, van Hooff JP. Echography of the inferior vena cava diameter is a simple and reliable tool for estimation of 'dryweight' in haemodialysis patients. Nephrol Dial Transplant 1989; 4: 563-568
19. Bert JL, Gyenge CC, Bowen BD, Reed RK, Lund T. A model of fluid and solid exchange in the human: validation and implications. Acta Physiol Scand 2000; 170: 201-209
20. Katzarski K, Nisell J, Randmaa I et al. A critical evaluation of ultrasound measurement of inferior vena cava diameter in assessing dry weight in normotensive and hypertensive hemodialysis patients. Am J Kidney Dis 1997; 30: 459-465
21. Paterakis GS, Laoutaris NP, Alexia SV et al. The effect of red cell shape on the measurement of red cell volume. A proposed method for the comparative assessment of this effect among various haematology analyzers. Clin Lab Haematol 1994; 16: 235-245
22. Britten GM, Brecher G, Johnson CA, Elashoff RM. Stability of blood in commonly used anticoagulants. Am J Clin Pathol 1969; 52: 690-694
23. Tzanakis I, Katoulis S, Girousis N et al. Prostate-specific antigen in hemodialysis patients and the influence of dialysis on its levels. Nephron 2002; 90: 230-233
24. Clyne N, Jogestrand T, Lins LE, Pehrsson SK. Progressive decline in renal function induces a gradual decrease in total hemoglobin and exercise capacity. Nephron 1994; 67: 322-326